This report provides exclusive insights into the COVID-19 impact on the Type 1 Diabetes Drugs Market. The detailed analysis provides information about the impact of the outbreak on the demand and supply conditions, trends and forecasts of the Type 1 Diabetes Drugs Market. Moreover, the impact analysis covers the study of the COVID-19 on the supply chain of Type 1 Diabetes Drugs Market. The sectoral impact shall provide insights into both short term and long term effects of the pandemic on the related and support industries.
A recent report published by Infinium Global Research on type 1
diabetes drugs market provides an in-depth analysis of segments and sub-segments
in global as well as regional type 1 diabetes drugs market. The study also
highlights the impact of drivers, restraints and macro indicators on the global
and regional type 1 diabetes drugs market over the short term as well as long
term. The report is a comprehensive presentation of trends, forecast and dollar
values of global type 1 diabetes drugs market. According to the report the global
type 1 diabetes drugs market is projected to grow at a CAGR of 7.4% over the
forecast period of 2018-2024.
The Type 1 diabetes drugs are
used to treat the type 1 diabetic disease and are also known as Type 1
diabetes mellitus. Type 1 diabetes is a condition where in the pancreas produce
very little or no insulin at all. Insulin is a hormone that allows sugar
(glucose) to enter cells to produce energy. People suffering from type 1
diabetes have to take daily insulin injection to keep body glucose in the normal
range. Without insulin injection, the patient may die. In type 1 diabetes
condition, the body’s immune system attacks & destroy most of the beta cells in
the pancreas. Different factors, including genetics and some viruses, may
contribute to type 1 diabetes. Although type 1 diabetes usually appears during
childhood or adolescence, however, it can also develop in adults.
Growing occurrence of type 1
diabetes is the major factor driving the type 1 diabetes drugs market. The
rising awareness about the type 1 diabetes and availability of its treatment
drugs, the introduction of new advanced insulin delivery devices such as pumps
& pens and improved drug delivery system is expected to boost the growth of
the type 1 diabetes drug market over the forecast period. However, the high cost of
insulin delivery systems, especially insulin pump and autoinjector may act as a
restraint to market growth. Moreover, the ongoing innovations in diabetes
drugs and the drug delivery system are projected to create several
opportunities in upcoming years.
Among the region, North America
is dominating the type 1 diabetes drugs market owing to the high occurrence of
diabetes among the population and adoption of new innovative insulin delivery
systems such as insulin pumps are the major factors that are driving the North
America region. The rapidly growing aging population and improved healthcare
infrastructure in the Asia Pacific region is likely to help to grow Asia
Pacific region at the highest CAGR, during the forecast period.
The report on global type 1 diabetes drugs market covers
segments such as type and end user. On
the basis of type, the global type 1 diabetes drugs market is categorized into
insulins and others. On the basis of end user, the global type 1 diabetes drugs
market is categorized into hospital, drugstore, and others.
The report provides regional analysis covering geographies such
as North America, Europe, Asia-Pacific, and Rest of the World. In this section, the key trends and market size for each geography are provided over the period
of 2016-2024. The countries covered in the North America region include the
U.S., Canada, and Mexico; while Asia-Pacific includes China, Japan, India,
South Korea, Malaysia, and among others. Moreover, Germany, U.K., France,
Spain and Rest of Europe are included in the European region. The U.S. drives
the growth in the North America region as it is the largest market in the
region. The Asia-pacific region offers a substantial potential for the market
growth owing to rapid growth in markets such as India and China. The APAC region is projected to experience a
growth at a CAGR of x.x% over the period of 2018-2024.
The report provides profiles of the companies in the global
type 1 diabetes drugs market such as Eli Lilly and Company, Novo Nordisk A/S,
XOMA Corp., Biodel, Inc., B.Braun Melsungen AG, AstraZeneca Plc., DiaVacs,
Inc., Biodel, Inc., and Macrogenics, Inc.
The report provides deep insights on demand forecasts, market
trends, and micro and macro indicators. In addition, this report provides
insights on the factors that are driving and restraining the global type 1
diabetes drugs market. Moreover, IGR-Growth Matrix analysis given in the report
brings an insight into the investment areas that existing or new market players
can consider. The report provides insights into the market using analytical
tools such as Porter's five forces analysis and DRO analysis of type 1 diabetes
drugs market. Moreover, the study highlights current market trends and provides
forecast from 2018-2024. We also have highlighted future trends in type 1
diabetes drugs market that will impact the demand during the forecast period.
Moreover, the competitive analysis given in each regional market brings an
insight on the market share of the leading players. This report will help
manufacturers, suppliers, and distributors of the type 1 diabetes drugs market
to understand the present and future trends in this market and formulate their